Jörg Ritter

Thomas Büchner

Wolfgang Hiddemann

Günther Schellong

Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.

Prognostic Factors and Treatment Strategies

Acute Leukemias II

This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.

Handbook of Acute Leukemia

Bernhard Wörmann

J. Ritter

William Plunkett

U. Creutzig

Michael J. Keating

150 years after the first description of the clinical picture of "white blood" and the introduction of the term "leukemia" by R. Virchow it appears, that the leukemias, and the acute leukemias in particular, serve as an impressive example for the major improvements that have been achieved in the treatment but also in the understand ing of the biology of malignant dis orders. The international symposia "Acute Leukemia" which are held at Münster since 1986 have developed into an interna tional forum to review the current progress and the future perspectives of leukemia research and therapy at a high scientific and clinicallevel. Since the possibility for active participation in these symposia is somewhat restricted we are glad to have the opportunity to extend the information that was presented at the symposium "Acute Leukemias V - Experimental Approaches and Management of Refractory Disease" which was held from February 27 to March 2, 1994 to a broader audience of basic scientists and clinicians. This meeting was especiaIly designed to discuss experimen tal approaches and the management of refractory disease which allows to evaluate new experimental therapies on the basis of preclinical studies.

Experimental Approaches and Management of Refractory Disease

Acute Leukemias V

Ursula Creutzig

The 7th volume of the book series Acute Leukemias provides new updates on the biology of acute leukemias and especially the underlying genetic and molecular events. High quality contributions are provided by leading scientists and clinicians making the book an excellent overview over most recent achievements which translate into new treatment strategies and hence an improved outlook for patients suffering from acute leukemias.

Experimental Approaches and Novel Therapies

Acute Leukemias VII

T. Haferlach

M. Unterhalt

Acute Leukemias IX provides an extended and thorough overview of recent developments in cell biology and experimental therapy for acute leukemias. Following the tradition of the Acute Leukemias series since 1987, this book bridges the gap between basic research and clinical studies and emphasizes that both aspects are equally necessary to achieve improvements, not only in understanding the disease but also in providing better therapy. As a forum for world-wide activities in the field of acute leukemias the volume contains invaluable contributions that provide the reader with new, previously unpublished information.

Basic Research, Experimental Approaches and Novel Therapies

Acute Leukemias IX

Günter Schellong

For 10 years the book series Acute Leukemias has been providing updates on the rapid progress being made internationally concerning this group of diseases. The fifth volume mainly addressed experimental approaches, but the present issue presents both therapeutic and prognostic aspects of the most recent results from major multicenter clinical trials. Additional chapters report new trends in leukemia cell biology,the monitoring of minimal residual disease, and secondary leukemias, as well as new antileukemic drugs, antimicrobial strategies, and the use of cytokines. The combined efforts against acute leukemias described in this book explain the recent improvements in the outcome of patients suffering from acute leukemias.

Wolfgang Hiddemann

About

Books

Join the club